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ABSTRACT 
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Background: The present study was aimed to determine the effect of Ger-
minated Barley Foodstuff (GBF) administration on serum C-reactive pro-
tein (CRP) levels and clinical signs in patients with Ulcerative Colitis (UC). 
Methods: Forty-six patients were randomly allocated into GBF group and 
control group. Subjects in control group received only conventional drug 
therapy, while the GBF group received 30g GBF per day (3 times a day) by 
oral administration during 2 month along with routine medications.  
Results: The mean serum CRP in the GBF group decreased significantly 
(P=0.017) compared with the baseline. Although the frequency of clinical 
signs including the number of episodes diarrhea, degree of visible blood in 
stool, degree of abdominal pain or cramping, nausea, vomiting, and anorex-
ia decreased in the GBF group but it was statistically significant only in the 
case of abdominal pain and cramping. However, this reduction was only 
significant in the case of abdominal pain and cramping (P=0.016) 
Conclusions: The consumption of GBF along with the current medication 
may be efficient in attenuating the inflammation and clinical signs of UC 
patients.  
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Introduction 
 
Inflammatory bowel disease (IBD) 
which includes two main forms, Crohn's 
disease and ulcerative colitis (UC), is a 
common disorder characterized by recur-
rent and serious inflammation of the ga-
strointestinal tract immunologically me-
diated.
1  The worldwide incidence and 
prevalence of IBD is constantly rising. 
Between 20,000 and 100,000 people are 
diagnosed with these diseases annually in 
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North America.
2 Although the highest in-
cidence and prevalence rates have been re-
ported from northern Europe, the UK, and 
North America, but these rates are continu-
ing to rise in low-incidence areas such as 
southern Europe, Asia, and most develop-
ing countries.
3 Patients suffer periodic at-
tacks of cramps, abdominal pain, diarrhea, 
fever, loss of appetite, rectal bleeding, muc-
ous in the stool, and weight loss.
4,5 IBD has 
a significant impact on an individual’s 
health-related quality of life.
6 UC is an idi-
opathic, chronic inflammatory disorder of 
the colon.
7 
The knowledge of the etiology and pa-
thogenesis of the inflammation in ulcera-
tive colitis is still insufficient.
8 The pathoge-
nesis of UC includes an abnormal immuno-
logical response to disturbed intestinal mi-
croflora.
9 Under normal situations, the in-
testinal mucosa is in a state of controlled 
inflammation regulated by a delicate bal-
ance of pro-inflammatoryand anti-
inflammatory cytokine and stimulation of 
the mucosal immune system through gut 
microbiota determining a state of low-grade 
physiological inflammation. Once this bal-
ance is disturbed, it induces abnormal im-
mune responses to luminal bacteria, dis-
turbs regulatory balance, increases produc-
tion and release of strong destructive im-
munological and inflammatory mole-
cules.
10-12 
Prebiotics are selectively fermented in-
gredients  which escape from digestion in 
the upper intestinal tract and allow specific 
changes both in the composition and/or 
activity of gastrointestinal microflora.
12,13 
Germinated barley foodstuff (GBF) is a 
prebiotic product derived from the aleu-
rone and scutellum fractions of germinated 
barley and consists of insoluble glutamine-
rich protein and dietary fiber.
13-15 
Since C-reactive protein (CRP) is an ob-
jective marker of inflammation in gastroin-
testinal diseases
16 and the clinical signs are 
common in UC.
17  Therefore, this study 
was aimed to investigate the effects of oral-
ly administered germinated barely foodstuff 
on serum CRP levels and clinical signs in 
ulcerative colitis patients in remission 
course. 
 
Material and Methods 
 
GBF preparation 
GBF  mainly consists of water-
insoluble dietary  ﬁbers  a nd glutamine-
rich proteins. The detailed production 
process of GBF was described previously. 
Briefly, after germination, barley is 
mashed and filtered to extract the endos-
perm, and then residue is milled and 
sieved to obtain germinated barley foods-
tuff.
13,15  
 
Subjects and treatments 
This study was an open-labeled trial as 
a pilot study. The participants (28 males 
and 18 females)  were selected from UC 
patients in remission course. In all pa-
tients, the disease activity was mild or 
moderate according to the Truelove & 
Witts criteria based on the number of f 
bloody stools per day, hemoglobin, Eryt-
hrocyte sedimentation rate (ESR), pulse 
rate and body temperature.
18 Exclusion cri-
teria were having UC disease in recurrence 
course or requiring hospitalization in the 
last 3 months, using pro or probiotic, anti-
oxidant and omega-3 supplements within the 
past 3 months, having any other disease or 
inflammatory condition and using corticoste-
roid drugs. UC diagnosis was confirmed by a 
gastroenterologist  based on clinical and en-
doscopic features. From a total of 46 partici-
pants, 29 had left-side colitis and 17 had pan-
colitis.  
Approval of this trial was granted by 
the Ethical Committee of the Nutrition 
and Food Sciences Institute, Shahid Be-
heshti University of Medical Sciences, 
Tehran, Iran. Besides, all subjects were Faghfoori et al.: Effects of an Oral Supplementation … 
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given an informed written consent to be 
completed and signed.  
The patients were randomly allocated 
into two groups: GBF group and control 
group (23 patients in each group). Sub-
jects in the control group received only 
conventional medications while the GBF 
group received orally administered of 30g 
germinated barley foodstuff per day (3 
times in a day) during 2 month along 
with conventional medications over the 
study. Pre-  and post-treatment values of 
serum hs-CRP  were measured using a 
commercial cytokine-specific ELISA kit 
according to the manufacturer’s instruc-
tions (Diagnostic Biochem Canada hs-
CRP Elisa kit). Clinical signs including 
the number of episodes diarrhea, degree 
of visible blood in stool, degree of abdo-
minal pain or cramping, nausea and vo-
miting, and anorexia were asked before 
and after the GBF treatment. 
Statistical Analysis 
Results were expressed as Mean ± SD. 
Thevariables were normally distributed 
using Kolmogorov–Smirnov test. Differ-
ences in mean values were analyzed with 
paired  t-test. McNemar test was used to 
analyze the effect of GBF on clinical 
signs. Statistical significance value was set 
at P <0.05. 
 
Results 
 
Three patients from the GBF group 
and two patients from the control group 
were excluded from the study because of 
using corticosteroid drugs (2 patients) and 
gastrointestinal discomfort (3 patients). 
Consequently, the data were analyzed for 
26 males and 15 females. The demograph-
ic characteristics and serum CRP levels of 
patients are presented in Table 1. 
No significant difference was found at 
baseline characteristics and pre-treatment 
serum CRP values between the two 
groups (P=0.17). Figure 1 presents the 
effect of GBF consumption on serum 
CRP values. The mean serum CRP in the 
GBF group decreased significantly (P= 
0.017) whereas there was a non-significant 
decrease in the control group (P= 0.46). 
The effects of GBF consumption on 
clinical signs of UC were shown in table 
2. The frequency of clinical signs reduced 
in GBF group; however, this reduction 
was only significant in the case of abdo-
minal pain and cramping (P=0.016). No 
significant differences were found in oth-
er variables in the control group over the 
study.  
 
Table 1: The baseline characteristics of participants in GBF and control groups 
 
 
Characteristic 
 
GBF
# 
n = 20 
Mean ± SD 
Control 
n = 21 
Mean ± SD 
 
P 
Age (yr)  33.90±11.76  33.04±12.41  0.77 
Weight(kg)  67.85±14.84  71.0±13.13  0.30 
Height(cm)  168.75±9.99  172.88±9.91  0.19 
BMI (kg/m
2)
  23.66±4.05  23.64±3.10  0.98 
Disease duration(yr)  5.25±3.09  5.47±1.91  0.77 
Started age of disease(year)  27.10±11.43  29.04±12.61  0.43 
Serum CRP (mg/L)  4.91±1.06*  3.20±0.64*  0.17 
# GBF, germinated barley foodstuff/ * Standard error of the mean (SEM)/ P values based on Indepen-
dent t tests. Health Promotion Perspectives, Vol. 4, No. 1, 2014; P: 116-121 
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Table 2: Comparison of frequency of patients with clinical signs before and after study 
 
 
 
 
 
Clinical 
sign 
GBF group(n=20)  P value  Control group(n=21)  P 
value  Before 
study 
N (%) 
After study 
N (%) 
Before 
study 
N (%) 
After study 
N (%) 
Increased 
clinical 
sign 
Reduced 
clinical sign 
(%) 
Not 
changed 
(%) 
Increased 
clinical sign 
 
Reduced 
clinical sign 
(%) 
Not 
changed 
(%) 
chronic diarr-
hea 
7(35.00)  -----  5(25.00)  -----  0.50  5(23.80)  1(4.76)  1(4.76)  2(9.52)  1.00 
visible blood 
in stool 
10(50.00)  -----  7(35.00)  1(5.00)  0.50  5(23.80)  1(4.76)  -----  4(19.04)  1.00 
abdominal 
pain or 
cramping 
10(50.00)  -----  2(10.00)  1(10/00)  0.01  9(42.9)  10(47.61)  2(9.52)  3(14.28)  0.07 
nausea and 
vomiting 
4(16.00)  -----  -----  1(5.00)  0.25  3(14.3)  2(9.52)  -----  1(4.76)  1.00 
Anorexia 
 
6(30.00)  -----  1(5.00)  -----  0.06  4(19)  1(4.76)  -----  3(14.28)  1.00 
P  values based on Mc Nemar tests 
 
Fig. 1: The effect of GBF consumption on serum CRP level (mg/L). Error bars show standard error of 
the mean 
 *P-value= 0.017/** P-value=0.46 
 
Discussion   
  
In  the present study, no side effects 
were observed on the consumption of 
germinated barley foodstuff. Although 
serum CRP levels decreased in both 
groups, only the reduction in the GBF 
group was statistically significant.  Since 
the common conventional medications 
were used in both groups over the study, 
the cause of this reduction were justifiable 
in the control group. To the best of our 
knowledge, there were limited studies as-
sessing the effect of GBF on serum levels 
of CRP in UC patients. The consumption 
of GBF in UC patients resulted in the re-
duction of some inflammatory markers 
such as serum CRP level.
19 
 
We observed a remarkable trend in the 
reduction of clinical signs in patients with 
UC after GBF consumption. Mitsuyama, 
et al. showed a significant improvement 
in clinical activity index scores in UC pa-
tients after 4 weeks of GBF consump-
tion.
19  The efficacy of GBF in UC pa-
tients in remission state showed that clin-
ical activity index values improved signif-
icantly in the GBF compared with the 
control group.
20  Besides, in Kanauchi et 
al. study, the GBF-treated group showed Faghfoori et al.: Effects of an Oral Supplementation … 
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a significant decrease in the clinical activi-
ty index scores (especially, the degree of 
visible blood in stools and the presence of 
nocturnal diarrhea) compared to the con-
trol.
21,22  At baseline 10 patients had re-
ported diarrhea while the episodes of di-
arrhea decreased in all patients and was 
eliminated in two cases after treatment. 
Solemn et al. showed that CRP elevation 
was significantly associated with severe 
clinical activity in UC patients.
23 In our 
study, GBF intervention could signifi-
cantly reduce CRP levels. Therefore, the 
observed favorable trend in the reduction 
of clinical signs after GBF consumption 
may be due to the reduction in CRP con-
centration.  Although the exact mechan-
ism of GBF action is not understood, it 
seems that it is due to butyrate produc-
tion by the administration of GBF. GBF 
or its fiber content significantly increases 
butyrate production in the lower intes-
tinal tract.
24 The previous studies showed 
butyrate ameliorates inflammation in ul-
cerative colitis.
25 
 
Conclusion 
 
This study showed the consumption of 
GBF along with routine medication in 
attenuates the inflammation and appears 
to be an effective and safe treatment in 
UC. On the other hand, it can prolong 
the remission course with an improve-
ment in clinical signs in these  patients. 
The present study was designed as a pilot 
study and the results may provide a basis 
for more future clinical trials to obtain 
the details of molecular and biological 
anti-inflammatory mechanism of GBF 
action. Further studies are required to ex-
amine the effect of GBF on different in-
flammatory factors. 
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